Health Canada Seized 11,400 Vials of Bacteria-Laced Peptides
November 8, 2026Best Resistant Starch in Canada (2026)
November 9, 2026Quick Summary
A Canadian team ran the exact same gut-health trial twice — same dose, same four weeks, same kind of volunteers — to see if the results would hold up. Mostly, they did: the resistant potato starch boosted Bifidobacterium, a friendly gut bug, and people had more normal stools. But the study’s main target, a microbe called Akkermansia, did not beat the placebo the second time. It is a rare, honest look at how supplement science works — and why a second trial matters more than a first.
Supplement studies almost never get a sequel. A company runs one trial, gets a good result, and moves on to marketing. So when a Manitoba starch maker ran its gut-health trial a second time — same dose, same four weeks, same kind of people — that alone was unusual. The twist: half the story checked out beautifully, and the other half quietly did not.
| Topic | What the research shows |
|---|---|
| Ingredient | Resistant potato starch (type 2), 3.5 g a day |
| Study | 4-week randomized, double-blind, placebo-controlled trial, 74 healthy adults, Guelph, Ontario |
| Reproduced | Bifidobacterium rose more than placebo; more normal stools (Bristol Type 3 or 4) |
| Did not | Akkermansia, the main target, did not beat placebo (p = 0.49) |
| Safety | No serious adverse events; gut-symptom scores unchanged |
| Catch | Lead author works for the company that makes the ingredient |
The study, run twice — on purpose
Here is why the rerun matters. In supplement research, a single good trial is treated as proof, and nobody ever checks it again. The prebiotic experts disagree: the International Scientific Association for Probiotics and Prebiotics (ISAPP) lists confirmatory evidence — a second trial showing the same thing — as the final step in proving an ingredient really counts as a prebiotic. Almost nobody takes that step. This team did.
The first trial, published in 2023, tested 3.5 g and 7 g a day against a placebo of fully digestible corn starch in 75 healthy adults over four weeks. Both doses raised Bifidobacterium and Akkermansia and cut down on constipation-type and diarrhea-type stools.
The new trial, published in October 2026 in Nutrients, repeated the recipe exactly: 3.5 g a day, four weeks, healthy adults aged 18 to 69, at a clinic in Guelph, Ontario. Of the 74 enrolled, 70 finished following the protocol — 35 on the starch, 35 on placebo. Everyone kept a daily bowel diary and gave stool samples for DNA sequencing of gut bacteria. The dose sounds small because it is: each 3.5 g serving held about 2.1 g of actual resistant starch.
What held up — and what did not
The Bifidobacterium win reproduced: people taking the starch saw their levels rise significantly more than the placebo group, just like the first trial. Stool form improved too. The starch group had more normal stools — Bristol Type 3 or 4, the smooth, easy-to-pass kind — than placebo (p = 0.0077), and more of them had a majority of normal bowel movements (p = 0.013). Days without a bowel movement fell by almost a full day over two weeks in the starch group, a change significantly bigger than placebo (p = 0.019). The placebo group did not change at all.
| Measure | What happened | Verdict |
|---|---|---|
| Bifidobacterium | Rose significantly more than placebo | Reproduced |
| Normal stools (Type 3–4) | More normal stools (p = 0.0077) | Reproduced |
| Days without a bowel movement | Down nearly a full day over 14 days (p = 0.019 vs placebo) | Reproduced |
| Akkermansia | Rose from baseline, but no better than placebo (p = 0.49) | Did not reproduce |
| Bowel movement frequency | Three more trips over 14 days, not different from placebo (p = 0.18) | Did not beat placebo |
Now the twist. Akkermansia was the study’s primary endpoint — the one result the trial was designed to prove. In 2023 it beat placebo. This time it did not. Levels did rise inside the starch group from where they started (p = 0.046), but the placebo group drifted up a little too, and the gap between groups was not significant (p = 0.49). A rise from your own baseline is not the same as beating a placebo, and the researchers say so plainly. That is the difference between a careful trial and a marketing claim — and exactly why running the study twice was worth doing.
The fine print worth knowing
First, the conflict of interest: the lead author is employed by the Manitoba company that makes the potato starch in the trial, and the study received no outside funding. That does not make the results wrong — the trial was randomized, double-blind, and placebo-controlled, run at an independent clinic with outside monitoring — but it belongs in the open, not buried. Second, the sample was small and the window short: 70 people who completed the protocol, all healthy adults, over four weeks. And the strictest analysis was weaker — counting everyone who took at least one dose, including a few who did not follow the protocol, the bacteria differences were no longer significant. The stool-form results held up either way.
One more Canadian note: the whole project is homegrown. The starch comes from a Manitoba company, both trials ran in Ontario, the work was conducted under Health Canada’s Natural Health Products Regulations, and type 2 resistant starch is recognized as a form of dietary fibre in Canada.
What is resistant starch — and how is it supposed to work?
Resistant starch is starch that refuses to be digested. Most starch breaks down into sugar in your small intestine. Resistant starch survives the trip and reaches your colon intact, where gut bacteria ferment it — and that fermentation is the whole point.
There are five types. Type 2 is the one in this trial: starch granules in their raw, natural shape that digestive enzymes cannot easily crack. Raw potato starch, green bananas, and high-amylose maize are the classic sources. Type 3 is the cooked-then-cooled kind — cold potatoes, cold pasta, cold rice — where heating and cooling rearranges starch into a digestion-proof crystal. Each type feeds different bacteria, so results for one kind cannot just be assumed for another.
When gut bacteria ferment resistant starch, they make short-chain fatty acids such as butyrate, which feed the cells lining your colon. Bifidobacterium is especially good at breaking it down, which is why researchers watch it so closely. A true prebiotic, by the ISAPP definition, is a substance gut microbes selectively use in a way that benefits your health. Resistant potato starch is unusual among fibres because it is insoluble yet fully fermentable — most insoluble fibres just add bulk and pass through.
What are the side effects of resistant starch?
At the dose used in these trials, the safety record was clean: no serious adverse events, gut-symptom scores did not worsen, and the only side effects judged possibly related were two reports of bloating — both in people taking the placebo.
That said, resistant starch is a fermentable fibre, and fermentable fibres can mean gas and bloating, especially as the dose climbs. The trials used a small dose — 3.5 g a day — and found no symptom changes at that level. Starting low is the sensible move.
One honest gap: both trials excluded people with irritable bowel syndrome and other digestive disorders, so nobody in these studies had a sensitive gut to begin with. If you have IBS or a similar condition, resistant starch is untested territory for you — worth a conversation with your doctor or pharmacist before trying it.
How much resistant starch should you take?
The dose with evidence behind it is small: 3.5 g a day of resistant potato starch, delivering about 2.1 g of true resistant starch. The 2023 trial also tested 7 g a day and found similar results, so doubling the dose did not obviously double the benefit.
For context, most people get very little from food — Americans average around 4 g a day, against suggested targets of 15 to 20 g a day. Studies chasing blood-sugar and metabolic effects have typically used much larger doses, 15 to 30 g a day. But those are different goals, and more is not automatically better with a fermentable fibre. The prebiotic effect here came from a teaspoon-sized dose, not a heaping scoop. Food helps too — a cold potato salad or a slightly green banana both contribute real resistant starch.
What should you look for on the label?
First, the form matters more than the brand: type 2 resistant potato starch — raw, unmodified potato starch. Heat destroys it, so stir the powder into cool or room-temperature water or food, never into something hot. Check the label for the actual resistant starch content per serving, not just the powder weight — in the trials, a 3.5 g serving delivered 2.1 g of resistant starch, about 60%.
Second, in Canada, look for a valid eight-digit NPN on the label. That number means Health Canada has licensed the product and reviewed its safety, quality, and claims. No NPN, no sale — and no reason to trust what is inside the bottle.
Third, look for third-party testing and a short, transparent ingredient list. Avoid proprietary blends that hide how much resistant starch is in each serving. If the label will not tell you the dose, you cannot match the dose the research used — and that is the number that matters.
References
- Bush, J. R., Iwuamadi, I., & Deehan, E. C. (2026). Examining the Gastrointestinal Effects of Solnul®, a Prebiotic Resistant Potato Starch: A Replication Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Healthy Adults. Nutrients, 18(21), 3538. https://www.mdpi.com/2072-6643/18/21/3538
- Bush, J. R., Baisley, J., Harding, S. V., & Alfa, M. J. (2023). Consumption of Solnul™ Resistant Potato Starch Produces a Prebiotic Effect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients, 15(7), 1582. https://www.mdpi.com/2072-6643/15/7/1582
- Hutkins, R., Walter, J., Gibson, G. R., et al. (2025). Classifying compounds as prebiotics — scientific perspectives and recommendations. Nature Reviews Gastroenterology & Hepatology, 22, 54–70. https://doi.org/10.1038/s41575-024-00981-6
This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.
